TNF and rheumatoid arthritis: According to FDA, anti-TNF agents licensed for clinical use in RA including infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab.14–18 Lots of clinical trials reported that patients in the duration of anti-TNF agent treatment developed hypertension,19–23 and hypertension should be seriously considered as possible adverse effects of anti-TNF agents.